Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice
Open accessThe DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
The tumor necrosis factor type 1 death receptor (TNFR1) contributes to apoptosis. TNFR1, a subgroup of the TNFR superfamily, contains a cytoplasmic death domain. We recently demonstrated that the TNFR1 cascade is required for amyloid β protein (Aβ)–induced neuronal death. However, the function of TNFR1 in Aβ plaque pathology and amyloid precursor protein (APP) processing in Alzheimer's disease (AD) remains unclear. We report that the deletion of the TNFR1 gene in APP23 transgenic mice (APP23/TNFR1−/−) inhibits Aβ generation and diminishes Aβ plaque formation in the brain. Genetic deletion of TNFR1 leads to reduced β-secretase 1 (BACE1) levels and activity. TNFR1 regulates BACE1 promoter activity via the nuclear factor-κB pathway, and the deletion of TNFR1 in APP23 transgenic mice prevents learning and memory deficits. These findings suggest that TNFR1 not only contributes to neurodegeneration but also that it is involved in APP processing and Aβ plaque formation. Thus, TNFR1 is a novel therapeutic target for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several lines of evidence had linked the inhibition of TNF-α signaling with reduction of both Aβ and tau pathologies in vivo36,37.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“The receptorinduced multimerization of a Fas-associated death domain protein leads to caspase activation, which causes degradation of specifi c target proteins, ultimately damaging cell integrity (Ashkenazi and Dixit, 1998).”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation
Hsu, H., Xiong, J., & Goeddel, D. V. (1995) · Cell · doi:10.1016/0092-8674(95)90070-5 · Cited by 2,012
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Skalli, O., Ropraz, P., Trzeciak, A., Benzonana, G., Gillessen, D., & Gabbiani, G. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.6.2787 · Cited by 1,621
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · cited 1×
“This might be because the APP transgene is controlled by different promoters in APP23 and Tg2576 mice (Irizarry et al., 1997; Sturchler-Pierrat et al., 1997).”
BackgroundSelf-citationFarris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Research works printed but not linked: 2
- 2003, Science., 299, 1014
- 2005, Med. Sci. Monit., 11, BR357
Cited by
Items 101–200 of 390
Gong, Q., Wang, Q., Pan, L., Liu, X., Xin, H., & Zhu, Y. Z. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.09.001 · Cited by 118
Chondrogianni, N., Voutetakis, K., Καπετάνου, Μ., Delitsikou, V., Papaevgeniou, N., Sakellari, M., Lefaki, M., Filippopoulou, K., & Gonos, E. S. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.003 · Cited by 127
Azzini, E., Peña‐Corona, S. I., Hernández‐Parra, H., Chandran, D., Saleena, L. A. K., Sawikr, Y., Peluso, I., Dhumal, S., Kumar, M., Leyva‐Gómez, G., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8200 · Cited by 133
“He et al., 2007).”
Microglia and inflammation: conspiracy, controversy or control?
Fernandes, A., Miller-Fleming, L., & Pais, T. F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1670-8 · Cited by 103
Precision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 110
Tan, L., Schedl, P., Song, H.-J., Garza, D., & Konsolaki, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003966 · Cited by 109
Menopause, obesity and inflammation: interactive risk factors for Alzheimer’s disease
Christensen, A., & Pike, C. J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00130 · Cited by 108
“For example, TNFRI knockout in AD transgenic mice diminishes AD-like neuropathology (He et al., 2007).”
BackgroundCytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice
Babcock, A. A., Ilkjær, L., Clausen, B. H., Villadsen, B., Dissing-Olesen, L., Bendixen, A. T. M., Lyck, L., Lambertsen, K. L., & Finsen, B. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.03.006 · Cited by 107
Bachstetter, A. D., Norris, C. M., Sompol, P., Wilcock, D. M., Goulding, D., Neltner, J. H., St. Clair, D., Watterson, D. M., & Van Eldik, L. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1496-12.2012 · Cited by 107
“Some studies have reported that interference with cytokine signaling by anti-inflammatory drug treatment or genetic deletion strategies results in reduced amyloid plaque load (Lim et al., 2000; Jantzen et al., 2002; Yan et al., 2003; Morihara et al., 2005; He et al., 2007; Yamamoto et al., 2007).”
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
“However, in another study, removal of TNF-α receptors also reduces plaque load (He et al., 2007), and supraphysiologic levels of this cytokine can be directly neurotoxic (Tan et al., 1999).”
Astrocytes in Alzheimer's Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity
Vincent, A. J., Gasperini, R., Foa, L., & Small, D. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101089 · Cited by 102
Cheng, X., Yang, L., He, P., Li, R., & Shen, Y. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1253 · Cited by 102
Self-citationMcAllister, C., Long, J., Bowers, A., Walker, A., Cao, P., Honda, S.-I., Harada, N., Staufenbiel, M., Shen, Y., & Li, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1180-10.2010 · Cited by 101
“In addition, to study the effect of testosterone on BACE transcription activity in vitro, we transfected 293 cells with pB1P-A vector containing a BACE1 promoter ( 1941 to 292) upstream as previous published (He et al., 2007).”
MethodSelf-citationJiang, H., Hampel, H., Prvulovic, D., Wallin, A., Blennow, K., Li, R., & Shen, Y. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-69 · Cited by 99
Self-citationGong, Q., Wang, Q., Pan, L., Liu, X., Huang, H., & Zhu, Y. Z. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.04.006 · Cited by 102
Guo, H.-S., Cheng, Y. F., Wu, J., Wang, C. M., Wang, H., Zhang, C., Qiu, Z. K., & Xu, J. P. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.058 · Cited by 102
He, P., Liu, Q., Wu, J., & Shen, Y. (2012) · The FASEB Journal · doi:10.1096/fj.11-192716 · Cited by 97
Self-citationInflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Ou, W., Yang, J., Simanauskaite, J., Choi, M., Castellanos, D. M., Chang, R., Sun, J., Jagadeesan, N., Parfitt, K. D., Cribbs, D. H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02332-7 · Cited by 95
Zhiyou, C., Yong, Y., Shanquan, S., Jun, Z., Liangguo, H., Ling, Y., & Li, J. (2009) · Neurochemical Research · doi:10.1007/s11064-008-9899-y · Cited by 107
Perspectives on neuroinflammation and excitotoxicity: A neurotoxic conspiracy?
Viviani, B., Boraso, M., Marchetti, N., & Marinovich, M. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.03.004 · Cited by 114
Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease
Taylor, J. M., Moore, Z., Minter, M. R., & Crack, P. J. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1745-4 · Cited by 97
Dubey, S., Heinen, S., Krantic, S., McLaurin, J., Branch, D. R., Hynynen, K., & Aubert, I. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908658117 · Cited by 94
Inflammation-sleep interface in brain disease: TNF, insulin, orexin
Clark, I. A., & Vissel, B. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-51 · Cited by 94
“physiological rise of soluble Aβ in awake subjects can be expected to follow, and be a consequence of, the increase in levels of inflammatory cytokines in the CSF of the human volunteers referred to previously [49], since APP expression [53-55] and its cleavage to Aβ [56-59] require increases in these mediators.”
BackgroundLipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases
Dekens, D. W., Eisel, U. L. M., Gouweleeuw, L., Schoemaker, R. G., Deyn, P. P. D., & Naudé, P. J. W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101414 · Cited by 96
Li, R., He, P., Cui, J., Staufenbiel, M., Harada, N., & Shen, Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8377-3 · Cited by 92
Self-citationReelin-mediated signaling in neuropsychiatric and neurodegenerative diseases
Knuesel, I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.002 · Cited by 89
“Moreover, inhibition of TNF receptor signaling in transgenic AD mice results in decreased Ab plaque formation (He et al., 2007).”
Distinct modes of TNF signaling through its two receptors in health and disease
Atretkhany, K. N., Gogoleva, V. S., Drutskaya, M. S., & Nedospasov, S. A. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mr0120-510r · Cited by 100
Necroptosis Mediates TNF-Induced Toxicity of Hippocampal Neurons
Liu, S., Wang, X., Li, Y., Xu, L., Yu, X., Ge, L., Li, J., Zhu, Y., & He, S. (2014) · BioMed Research International · doi:10.1155/2014/290182 · Cited by 95
Interventions for age-related diseases: Shifting the paradigm
Figueira, I., Fernandes, A., Mladenovic Djordjevic, A., Lopez-Contreras, A., Henriques, C. M., Selman, C., Ferreiro, E., Gonos, E. S., Trejo, J. L., Misra, J., et al. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.009 · Cited by 87
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., De Felice, F. G., & Lourenco, M. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179911 · Cited by 87
Xuan, A., Xue-bing, P., Wei, P., Ji, W., Zhang, W.-J., Liu, J., Hong, L.-P., Chen, W., & Long, D. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8751-4 · Cited by 94
Clark, I. A., & Vissel, B. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13181 · Cited by 84
“…DAMP character of Aβ, in line with that of HMGB1 and the S100 proteins, requires an awareness that the proinflammatory cytokines that mediate the harm caused by Aβ had also been instrumental in inducing Aβ (Liao et al., 2004; He et al., 2007; 2013; Yamamoto et al., 2007; Zhao et al., 2011).”
BackgroundHigh Activities of BACE1 in Brains with Mild Cognitive Impairment
Cheng, X., He, P., Lee, T., Yao, H., Li, R., & Shen, Y. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.10.002 · Cited by 83
Self-citationWang, R., Chen, S., Liu, Y., Diao, S., Xue, Y., You, X., Park, E. A., & Liao, F.-F. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662908 · Cited by 82
“Neurons may directly respond to inflammatory agents due to neuronal expression of cytokine receptors such as the LPS and TNF receptors (42, 43).”
BackgroundEarly Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 85
Fernandez, A. M., Jiménez, S., Mecha, M., Dávila, D., Guaza, C., Vitórica, J., & Torres‐Alemán, I. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.128 · Cited by 93
Molecular Basis of Etiological Implications in Alzheimer’s Disease: Focus on Neuroinflammation
Niranjan, R. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8428-4 · Cited by 87
Impaired peripheral glucose homeostasis and Alzheimer's disease
Wijesekara, N., Gonçalves, R. A., De Felice, F. G., & Fraser, P. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.027 · Cited by 80
“The deletion of TNFa receptors was also protective against cognitive decline and AD-like brain changes in mice models of AD (He et al., 2007; Lourenco et al., 2013).”
Cavanagh, C., Tse, Y. C., Nguyen, H.-B., Krantic, S., Breitner, J. C. S., Quirion, R., & Wong, T. P. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.009 · Cited by 79
Pihlaja, R., Takkinen, J., Eskola, O., Vasara, J., López-Picón, F. R., Haaparanta-Solin, M., & Rinne, J. O. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0305-9 · Cited by 79
Chavant, F., Deguil, J., Pain, S., Ingrand, I., Milin, S., Fauconneau, B., Pérault‐Pochat, M. C., & Lafay‐Chebassier, C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162164 · Cited by 87
“Thus, in APP23 mice, TNFR1 deletion reduces A generation and microglia activation, and prevents learning and memory deficits (He et al., 2007).”
BackgroundChun, H., Marriott, I., Lee, C. J., & Cho, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00797 · Cited by 77
Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease
Ortí-Casañ, N., Wu, Y., Naudé, P. J. W., De Deyn, P. P., Zuhorn, I. S., & Eisel, U. L. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00049 · Cited by 77
“Similarly, deletion of TNFR1 in an AD mouse model resulted in a reduction in the generation of Aβ plaques and an enhancement in learning and memory (He et al., 2007; Olleros et al., 2010), indicating the contribution of TNFR1 to neurodegeneration.”
BackgroundAnwar, S., & Rivest, S. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1738391 · Cited by 77
Paouri, E., Tzara, O., Kartalou, G.-I., Zenelak, S., & Georgopoulos, S. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2484-16.2017 · Cited by 76
“Genetic ablation of TNF receptor-1 or administration of TNFinhibitors in AD mice results in attenuation of the amyloid phenotype (He et al., 2007; McAlpine et al., 2009; Shi et al., 2011b; Tweedie et al., 2012; Gabbita et al., 2015), suggesting that inhibition of TNF- signaling confers a protective…”
BackgroundIntegrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration
van Dijk, G., van Heijningen, S., Reijne, A. C., Nyakas, C., van der Zee, E. A., & Eisel, U. L. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00173 · Cited by 75
“The fact that transgenic mice with deletion of TNFR1 show a significant decline in microglia activation, BACE1 activity, Aβ pathology, less memory deficits and less neuron loss indeed suggest a role for TNRF1 in the pathogenesis of AD (He et al., 2007).”
BackgroundPoon, C. H., Wang, Y., Fung, M.-L., Zhang, C., & Lim, L. W. (2020) · Aging and disease · doi:10.14336/ad.2019.1026 · Cited by 73
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Jalouli, M., Rahman, M. A., Jeandet, P., Behl, T., Alexiou, A. T., Albadrani, G. M., Abdel‐Daim, M. M., Perveen, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210826130210 · Cited by 81
“Interestingly, it has been observed that TNFR1 gene deletion in APP transgenic mice decreases the deposition of plaque and also improves cognitive impairment by the down-regulating activity of the BACE1 promoter [74].”
BackgroundHe, P., Cheng, X., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055091 · Cited by 73
Self-citationβ-Secretase: its biology as a therapeutic target in diseases
Wang, H., Li, R., & Shen, Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.008 · Cited by 69
Self-citationAzizi, G., & Mirshafiey, A. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2012.705292 · Cited by 73
Grochowska, K. M., Yuanxiang, P., Bär, J., Raman, R., Brugal, G., Sahu, G., Schweizer, M., Bikbaev, A., Schilling, S., Demuth, H., et al. (2017) · EMBO reports · doi:10.15252/embr.201643519 · Cited by 73
TNFα induces survival through the FLIP-L-dependent activation of the MAPK/ERK pathway
Marques-Fernandez, F., Planells-Ferrer, L., Gozzelino, R., Galenkamp, K. M., Reix, S., Llecha-Cano, N., Lopez-Soriano, J., Yuste, V. J., Moubarak, R. S., & Comella, J. X. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.25 · Cited by 71
Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice
Xie, K., Liu, Y., Hao, W., Walter, S., Penke, B., Hartmann, T., Schachner, M., & Fassbender, K. C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.013 · Cited by 72
“Tnc deficiency reduces high molecular-weight Ab aggregates in the APPtg mouse brain Ab is a pathogenic molecule in AD and its generation is influenced by inflammatory activation (He et al., 2007; Sheng et al., 2003).”
Dekens, D. W., Naudé, P. J. W., Keijser, J. N., Boerema, A. S., Deyn, P. P. D., & Eisel, U. L. M. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1372-5 · Cited by 71
Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease
Yang, S.-H. (2019) · International Neurourology Journal · doi:10.5213/inj.1938184.092 · Cited by 68
Wang, M., Cheng, X.-Y., Jin, M., Cao, Y.-L., Yang, Y., Wang, J.-D., Li, Q., Wang, F., Hu, L., & Liu, C. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.008 · Cited by 71
Kiyota, T., Yamamoto, M., Schroder, B., Jacobsen, M. T., Swan, R. J., Lambert, M. P., Klein, W. L., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2009) · Molecular Therapy · doi:10.1038/mt.2009.44 · Cited by 68
Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor
Zhou, Q.-H., Sumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185876 · Cited by 68
“TNF- also plays a pathologic role in brain disorders, including Parkinson’s disease (PD) (McCoy et al., 2006), Alzheimer’s disease (He et al., 2007), and depression (Himmerich et al., 2008).”
BackgroundCao, Z., Yang, J., Xu, R., Song, Q., Zhang, X., Liu, H., Qiang, X., Li, Y., Tan, Z., & Deng, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.030 · Cited by 69
Necroptosis: Who Knew There were so Many Interesting Ways to Die?
Fayaz, S. M., Kumar, V. S. S., & Rajanikant, G. K. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660189 · Cited by 70
CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection
Chen, P., Zhao, W., Guo, Y., Xu, J., & Yin, M. (2016) · BioMed Research International · doi:10.1155/2016/8090918 · Cited by 64
Interpreting crosstalk between TNF-α and NGF: potential implications for disease
Takei, Y., & Laskey, R. A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.07.002 · Cited by 69
ROCK, PAK, and Toll of synapses in Alzheimer’s disease
Salminen, A., Suuronen, T., & Kaarniranta, K. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.148 · Cited by 71
MyD88 Deficiency Ameliorates β-Amyloidosis in an Animal Model of Alzheimer's Disease
Lim, J.-E., Kou, J., Song, M., Pattanayak, A., Jin, J., Lalonde, R., & Fukuchi, K.-I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.045 · Cited by 63
Zhang, H., Peng, J., Cheng, X.-B., Shi, B., Zhang, M., & Xu, R. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1632-z · Cited by 65
Mishra, P., Silva, A., Sharma, J., Nguyen, J., Pizzo, D. P., Hinz, D., Sahoo, D., & Cherqui, S. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112956 · Cited by 65
“Finally, comprehensive understanding of the mechanism underlying the behavioral rescue in AD by WT HSPCs remains to be discovered.”
BACE1 as a Potential Biomarker for Alzheimer's Disease
Decourt, B., & Sabbagh, M. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110017 · Cited by 61
Wang, Q., Xiao, B., Cui, S., Song, H., Qian, Y., Dong, L., An, H., Cui, Y., Zhang, W., He, Y., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018218 · Cited by 68
“It has been reported that inflammation and oxidative stress upregulate the expression of BACE1 (Wang et al., 2013a) and that the TNFα and TNF receptor 1 cascade is involved in APP processing and the formation of Aβ plaques (He et al., 2007).”
BackgroundPark, J., Lee, S., Shon, J., Kim, K., Lee, H. J., Kim, K., Lee, B.-Y., Oh, S., KIM, N. K., & Kim, O. J. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.04.054 · Cited by 61
Gabbita, S. P., Johnson, M. F., Kobritz, N., Eslami, P., Poteshkina, A., Varadarajan, S., Turman, J., Zemlan, F., & Harris-White, M. E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137305 · Cited by 60
Paouri, E., Tzara, O., Zenelak, S., & Georgopoulos, S. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170065 · Cited by 60
Anitua, E., Pascual, C., Antequera, D., Bolós, M., Padilla, S., Orive, G., & Carro, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.009 · Cited by 64
Is There a Causal Link between Inflammation and Dementia?
Enciu, A., & Popescu, B. O. (2013) · BioMed Research International · doi:10.1155/2013/316495 · Cited by 63
“In vitro,TLR3 activation enhances neuronal survival and endothelial cell growth, promoting neuroprotective responses rather than pro-inflammatory signals [32].”
BackgroundInflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Sastre, M., C. Richardson, J., M. Gentleman, S., & J. Brooks, D. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256062 · Cited by 59
Mesenchymal stem cell-mediated immunomodulation in cell therapy of neurodegenerative diseases
Chen, X., Wang, S., & Cao, W. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.06.006 · Cited by 66
Muthukumaran, K., Kanwar, A., Vegh, C., Marginean, A., Elliott, A., Guilbeault, N., Badour, A., Sikorska, M., Cohen, J., & Pandey, S. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170275 · Cited by 59
Targeting Alzheimer's disease with gene and cell therapies
Loera‐Valencia, R., Piras, A., Ismail, M.-A.-M., Manchanda, S., Eyjolfsdottir, H., Saido, T. C., Johansson, J., Eriksdotter, M., Winblad, B. G., & Nilsson, P. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12759 · Cited by 60
Montgomery, S. L., Narrow, W. C., Mastrangelo, M. A., Olschowka, J. A., O'Banion, M. K., & Bowers, W. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.030 · Cited by 58
IL‐27 inhibits OSM‐mediated TNF‐α and iNOS gene expression in microglia
Baker, B. J., Park, K. W., Qin, H., Ma, X., & Benveniste, E. N. (2010) · Glia · doi:10.1002/glia.20989 · Cited by 60
“…abolishes the expression of proinflammatory cytokines and is protective in several animal models of neuroinflammation, including ischemia, traumatic brain injury, PD, AD, and MS (Allan and Rothwell, 2001; He et al., 2007; McCoy et al., 2006, 2008; Nadeau and Rivest, 2000; Selmaj et al., 1995).”
BackgroundDelaby, C., Gabelle, A., Blum, D., Schraen-Maschke, S., Moulinier, A., Boulanghien, J., Séverac, D., Buée, L., Rème, T., & Lehmann, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00181 · Cited by 57
Shin, J., Lee, J. K., Lee, J. E., Min, W., Schuchman, E. H., Jin, H. K., & Bae, J. (2011) · STEM CELLS · doi:10.1002/stem.659 · Cited by 57
Hao, W., Liu, Y., Liu, S., Walter, S., Grimm, M. O., Kiliaan, A. J., Penke, B., Hartmann, T., Rübe, C. E., Menger, M. D., et al. (2011) · Brain · doi:10.1093/brain/awq325 · Cited by 56
“Alternatively, inflammation could have modulated expression of Ab precursor protein and b-secretase 1 as previously reported (Grilli et al., 1995; He et al., 2007; Buggia-Prevot et al., 2008).”
Labarta-Bajo, L., & Allen, N. J. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.010 · Cited by 69
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 54
“Consistent with the role of TNF in regulation of APP processing, genetic deletion of the TNF receptor gene Tnfrsf1a in the APP 23 transgenic mouse model reduced both the number of amyloid plaques and the cognitive defi cits in these mice (He et al 2007).”
BackgroundKim, M. L., Zhang, B., Mills, I. P., Milla, M. E., Brunden, K. R., & Lee, V. M.-Y. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2913-08.2008 · Cited by 53
“Interestingly, deletion of TNF type I receptor (TNFR1, p55) gene in APP23 transgenic mice diminished amyloid plaque formation and improved cognitive deficits by downregulating BACE1 promoter activity (He et al., 2007).”
BackgroundDeficiency of GDNF Receptor GFRα1 in Alzheimer's Neurons Results in Neuronal Death
Konishi, Y., Yang, L., He, P., Lindholm, K., Lu, B., Li, R., & Shen, Y. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2582-13.2014 · Cited by 59
“Western blotting was performed as described previously (He et al., 2007).”
MethodSelf-citationJiang, L., Li, X., Mortadza, S. A. S., Lovatt, M., & Yang, W. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.002 · Cited by 55
Mukhara, D., Oh, U., & Neigh, G. N. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00017-5 · Cited by 69
Role of S5b/PSMD5 in Proteasome Inhibition Caused by TNF-α/NFκB in Higher Eukaryotes
Shim, S. M., Lee, W., Kim, Y., Chang, J. W., Song, S., & Jung, Y. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.013 · Cited by 53
Self-citationBAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathology
Zhang, L., Qian, Y., Li, J., Zhou, X., Xu, H. J., Yan, J., Xiang, J., Yuan, X., Sun, B., Sisodia, S. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102942 · Cited by 57
“TNFa is known to involve in AD via promoting neuroinflammation and neuronal death (He et al., 2007) and inflammatory microglia secreted TNFa contributes to neuronal apoptosis via activating neurotoxic A1 astrocytes in AD (Liddelow et al., 2017).”
BackgroundPharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task
Cassano, T., Calcagnini, S., Carbone, A., Bukke, V. N., Orkisz, S., Villani, R., Romano, A., Avolio, C., & Gaetani, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01067 · Cited by 50
“Moreover, the deletion of TNFR1 causes a reduction of both Aβ production and microglia activation as well as ameliorates the cognitive deficits in APP23 mice (He et al., 2007).”
BackgroundAnti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-Κb to Halt Alzheimer's Disease
Uddin, M. S., Hasana, S., Ahmad, J., Hossain, M. F., Rahman, M. M., Behl, T., Rauf, A., Ahmad, A., Hafeez, A., Perveen, A., et al. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118092422 · Cited by 49
Acosta, S. A., Tajiri, N., Sanberg, P. R., Kaneko, Y., & Borlongan, C. V. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25629 · Cited by 49
“In support of the dysfunctional immune system hypothesis, deleting the TNFR1 in transgenic mice prevents learning and memory impairments (He et al., 2007).”
BackgroundEl-Gazar, A. A., Soubh, A. A., Mohamed, E. A., Awad, A. S., & El-Abhar, H. S. (2019) · Brain Research · doi:10.1016/j.brainres.2019.04.003 · Cited by 51
Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD
Gross, A. L., Walker, K. A., Moghekar, A. R., Pettigrew, C., Soldan, A., Albert, M. S., & Walston, J. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00229 · Cited by 49
“In animal models, TNFR1 is associated with amyloidosis and APP processing (He et al., 2007; Paouri et al., 2017).”
BackgroundDong, Y., Dekens, D. W., Deyn, P. P. D., Naudé, P. J. W., & Eisel, U. L. M. (2015) · Antibodies · doi:10.3390/antib4040369 · Cited by 56
Sleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway
Pak, V. M., Onen, S. ‐., Bliwise, D. L., Kutner, N. G., Russell, K. L., & Onen, F. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00069 · Cited by 56
Metadata
- Authors
- He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y.
- Affiliations
- Banner Sun Health Research Institute (US)
- 1Haldeman Laboratory of Molecular and Cellular Neurobiology
- Brigham and Women's Hospital (US)
- Novartis (Switzerland) (CH)
- Corresponding author
- Shen, Yong
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2007-08-27
- Volume
- 178
- Issue
- 5
- Pages
- 829-841
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2064547
- OpenAlex
- W2096277075
- Cited by
- 390
- References
- 76
- Citations by year
- 2026: 16 · 2025: 12 · 2024: 27 · 2023: 11 · 2022: 18 · 2021: 21 · 2020: 23 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 15 · 2015: 30 · 2014: 35 · 2013: 24 · 2012: 18
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG025888, AG025888)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tumor necrosis factor receptor 1, Alzheimer's disease, amyloid-beta production, amyloid plaques, APP processing, beta-secretase 1, BACE1, NF-κB signaling, APP23 transgenic mice, learning and memory impairment, neurodegeneration, death receptor signaling
- MeSH terms
- Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Gene Expression Regulation, Humans, Insulysin, Learning, Memory Disorders, Mice, Transgenic, Neurons, Promoter Regions, Genetic, Tumor Necrosis Factor-alpha, Neprilysin, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, NF-kappa B, Cerebral Amyloid Angiopathy, Gene Deletion, Microglia, Mice, Knockout, Receptors, Tumor Necrosis Factor, Type I, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.